CLINICAL TRIALS PROFILE FOR NESIRITIDE
✉ Email this page to a colleague
All Clinical Trials for NESIRITIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00075179 ↗ | Natrecor in Pulmonary Hypertension | Terminated | M.D. Anderson Cancer Center | Phase 4 | 2003-12-31 | The goal of this clinical research study is to learn if the drug nesiritide (Natrecor) is effective in lowering the pressure in your lungs. The primary objective of this study is to establish that Nesiritide (Natrecor) is effective in reducing pulmonary hypertension (PHTN) acutely as measured by a 20% reduction in the mean pulmonary arterial (PA) pressure. The secondary objectives will include: improvement in pulmonary vascular resistance (PVR), patient symptoms, exercise tolerance, frequency of toxicity, and surgeon's willingness to proceed with operation. |
| NCT00083772 ↗ | Use of Nesiritide in the Management of Acute Diastolic Heart Failure | Terminated | M.D. Anderson Cancer Center | Phase 4 | 2004-05-17 | Primary objective is to assess the effect of nesiritide in decreasing left ventricular (LV) filling pressure, defined as pulmonary artery capillary wedge pressure (PCWP) in a group of patients admitted with acute diastolic heart failure. Secondary objectives include: improvement in symptoms, exercise tolerance, improvement in Doppler diastolic filling parameters in patients with diastolic heart failure. |
| NCT00091520 ↗ | A Study of the Safety and Efficacy of Follow-up Serial Infusions of Natrecor(Nesiritide) for the Management of Patients With Heart Failure | Completed | Scios, Inc. | Phase 2 | 2004-04-01 | The purpose of this study is to evaluate the efficacy and safety of Nesiritide administered as serial infusions to heart failure (HF) patients in the outpatient setting. |
| NCT00110201 ↗ | The Use of Nesiritide in Thoracic Aneurysm Repair to Prevent Acute Renal Failure | Unknown status | Ejaz, Abulate A, MD | Phase 3 | 2005-03-01 | The purpose of this trial is to study the use of nesiritide in thoracic aneurysm repair to prevent acute renal failure. The study hypothesis: Nesiritide, given prophylactically prior to surgery may prevent acute renal failure requiring dialysis and/or decrease mortality. |
| NCT00119691 ↗ | Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction | Completed | Scios, Inc. | Phase 2 | 2003-04-01 | The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone. |
| NCT00119691 ↗ | Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction | Completed | Brigham and Women's Hospital | Phase 2 | 2003-04-01 | The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone. |
| NCT00145873 ↗ | Nesiritide in Chronic Heart Failure | Terminated | Scios, Inc. | Phase 2 | 2003-08-01 | The purpose of this study is to look at the safety and effectiveness of longer term intravenous (IV) infusion of the study drug, nesiritide in patients with acutely decompensated chronic heart failure. Nesiritide (Natrecor) is a man-made version of a human hormone that dilates veins and arteries. Nesiritide (Natrecor) is currently FDA-approved for short-term inpatient IV treatment of acutely decompensated chronic heart failure. Hypothesis: Nesiritide, administered by continuous intravenous infusion in the outpatient setting, is a safe treatment for refractory Class III & IV chronic heart failure due to systolic or diastolic dysfunction, regardless of renal function when administered over a 12-week period. Corollary #1: Nesiritide, when infused continuously over 12 weeks will improve the overall condition of patients with chronic heart failure. These mechanisms include reducing hospitalizations when compared with the previous six months, improving symptoms as measured by the Minnesota Living with Heart Failure short questionnaire, and improving functional capacity as measured by 6-minute walk testing. Corollary #2: Nesiritide infusion will be associated with a statistically significant decrease in N-terminal pro-BNP levels and cyclic GMP levels compared with patients receiving placebo infusions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NESIRITIDE
Condition Name
Clinical Trial Locations for NESIRITIDE
Trials by Country
Clinical Trial Progress for NESIRITIDE
Clinical Trial Phase
Clinical Trial Sponsors for NESIRITIDE
Sponsor Name
